Case Report Brodie's Abscess in a Patient Presenting with Sickle Cell Vasoocclusive Crisis

First described by Sir Nicholas Brodie in 1832, Brodie's abscess is a localized subacute or chronic infection of the bone, typically seen in the metaphases of long bones in children and adolescents. The diagnosis can prove to be enigmatic due to absence of clinical signs and symptoms of systemic disease. We report a very interesting case of Brodie's abscess masquerading as sickle cell vasoocclusive crisis in a 20-year-old female with sickle cell disease and review the literature

Understanding cardio-oncology and potential impacts on patients

Cardio-oncology is a new multidisciplinary field that involves the management of cardiovascular side effects in patients receiving anti-cancer therapies . Recent advances in clinical oncology resulted in an increased number of anti-cancer drugs that have a direct effect on the heart. Early diagnosis, prevention, risk stratification, early treatment and serial monitoring are the major principles of cardio-oncology. Although some patients experience cardiotoxicity secondary to anti-cancer treatment, the rest complete their treatment without any alteration in cardiac functions. Risk factors may have an effect on developing cardiotoxicity in patients receiving cardiotoxic anti-cancer drugs. Optimal management of cardio-oncology patients should be based on inter-professional collaboration. • To provide an overview of cardio-oncology and the role of the pharmacists to provide proactive care • To introduce the importance of real-world evidence and the possible impact of different risk factors in developing cardiotoxicity. • To showcase the risk of cardiotoxicity in people with lung and breast cance

Brodie’s Abscess in a Patient Presenting with Sickle Cell Vasoocclusive Crisis

First described by Sir Nicholas Brodie in 1832, Brodie’s abscess is a localized subacute or chronic infection of the bone, typically seen in the metaphases of long bones in children and adolescents. The diagnosis can prove to be enigmatic due to absence of clinical signs and symptoms of systemic disease. We report a very interesting case of Brodie’s abscess masquerading as sickle cell vasoocclusive crisis in a 20-year-old female with sickle cell disease and review the literature

Investigating the efficacy of osimertinib and crizotinib in phase 3 clinical trials on anti-cancer treatment-induced cardiotoxicity: are real-world studies the way forward?

Peer reviewed: TrueBACKGROUND.: Oncology clinical trials demonstrate the risk of cardiotoxicity but are not sufficient to reveal the true risk. In this article, we compared the incidence of cardiotoxicity of crizotinib and osimertinib from a real-world study to data reported by phase 3 clinical trials. METHODS.: Data from an ongoing real-world lung cancer study was used as a comparator. Patients were recruited retrospectively with the criteria of being diagnosed with non-small cell lung cancer and having received at least a course of treatment of tyrosine-kinase inhibitor and/or immune check-point inhibitor. Characteristics of the patients who developed cardiotoxicity associated with osimertinib and crizotinib in the real-world lung cancer study were analysed against the inclusion criteria of the corresponding phase 3 clinical trials. Variations of cardiotoxicity incidence among the real-world lung cancer study and clinical trials were investigated. RESULTS.: 18%, n = 37/206, of the patients developed cardiotoxicity. QTc prolongation was the most frequently observed cardiotoxicity (n = 12/37). Osimertinib and crizotinib were the most cardiotoxic agents, each responsible for seven cases of cardiotoxicity. FLAURA, AURA3, PROFILE 1007 and PROFILE 1014 were the included clinical trials for analysis. None of the patients who developed cardiotoxicity in the real-world study would have been eligible to participate in FLAURA and PROFILE 1014 study whereas n = 4/7 and n = 5/7 patients were eligible to participate in AURA3 and PROFILE 1007 trials, respectively. CONCLUSION.: Although phase 3 clinical trials play an important role in understanding the effectiveness and give insights on side-effect profiles, real-world studies can show the real risk of cardiotoxicity more accurately and realistically

sj-docx-1-opp-10.1177_10781552231164301 - Supplemental material for Multiple cardiotoxicities during osimertinib therapy

Supplemental material, sj-docx-1-opp-10.1177_10781552231164301 for Multiple cardiotoxicities during osimertinib therapy by Hasan Kobat, Michael Davidson, Islam Elkonaissi, Emma Foreman and Shereen Nabhani-Gebara in Journal of Oncology Pharmacy Practice</p

Lemierre's syndrome resulting from streptococcal induced otitis media and mastoiditis: a case report

Abstract Introduction Lemierre's syndrome is an extremely rare and almost universally fatal disease characterized as thrombophlebitis of the internal jugular venous system with subsequent metastatic infection. Fusobacterium necrophorum is the most common organism implicated in causation of Lemierre's syndrome. Group A Streptococcus has mainly been observed as a polymicrobial organism in the syndrome. We report a rare finding of a rare disease where Group A Streptococcus was the sole organism triggering Lemierre's syndrome. To our knowledge, this is only the third recorded patient with such an occurrence. Case presentation We describe a 9-year-old African American boy, who presented with otitis media and mastoiditis that culminated in Lemierre's syndrome. Isolates bore only Group A Streptococcus. The patient was appropriately treated and responded with full recovery from the syndrome. Conclusion Since Lemierre's syndrome is classically detected by clinical diagnosis, these findings should prompt clinicians to consider Group A Streptococcus as an alternative catalyst. It should be pondered that patients who present with typical Group A streptococcal infections have the possibility for developing Lemierre's syndrome. Though this complication appears to be rare, early diagnosis and prompt intervention have proven critical in survival outcome. Indeed, what would seem to be a routine case of strep throat or otitis media easily treated with antibiotics could end up being an unalterable progression to death unless Lemierre's syndrome is immediately diagnosed and treated.</p